1. LC–MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma
   Shiyi Liu et al, 2018, Bioanalysis CrossRef
2. Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
   Mi Zhang et al, 2021, Thoracic Cancer CrossRef
3. Combinational therapies for the treatment of advanced cervical cancer
   Alfonso Duenas-Gonzalez, 2023, Expert Opinion on Pharmacotherapy CrossRef
4. Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
   Aini Hyytiäinen et al, 2021, Frontiers in Oncology CrossRef
5. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
   Ting Li et al, 2022, Cancer Chemotherapy and Pharmacology CrossRef
6. Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging)
   Chen Huang et al, 2024, Current Drug Delivery CrossRef
7. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study
   Yunzhe Huang et al, 2023, Expert Opinion on Drug Metabolism & Toxicology CrossRef
8. The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
   Massimiliano Salati et al, 2021, Cancer Management and Research CrossRef
9. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects
   Linlin Hu et al, 2022, Investigational New Drugs CrossRef